



October 08, 2025

To,
Listing/ Compliance Department
BSE LTD.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

SCRIP CODE: 543748

To,
Listing/ Compliance Department
**National Stock Exchange of
India Limited**
"Exchange Plaza", Plot No. C/1,
G Block, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
SYMBOL: AARTIPHARM

Dear Sir/Madam,

**Sub: Ex-parte ad-interim injunction order regarding
pharmaceutical drug product containing
Ruxolitinib and/or Ruxolitinib Phosphate API**
**Ref: Regulation 30 of SEBI (LODR) Regulations,
2015 ('Listing Regulations')**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform the Exchanges that the Company has received an ex-parte ad-interim injunction Order from the Hon'ble High Court of Delhi, New Delhi restraining the Company from manufacturing, stockpiling, exporting, offering for sale and/or supplying, directly or indirectly, the pharmaceutical drug product containing the compound Ruxolitinib and/or Ruxolitinib Phosphate API along with any other form or compound or formulation which would amount to infringement of the Suit Patent bearing No. IN269841

Further, Local Commissioner and its team visited the office premises of the Company to inspect and took relevant copies of ledgers, stock registers etc.

The Company fully co-operated with the officials during the proceedings and responded to the clarifications and details sought by them.

The business operations of the Company continued as usual and were not impacted due to the search.

The details as required under Clause 20 of Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed as Annexure A.

Please take the same on your records.

Thanking you,

Yours faithfully,

For AARTI PHARMALABS LIMITED

JEEVAN MONDKAR
COMPANY SECRETARY AND LEGAL HEAD

Encl.: a/a

AARTI PHARMALABS LIMITED

www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@aartipharmalabs.com

Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234
Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655

Annexure A

Sr. No.	Particulars	Remarks
1.	Name of the authority	High Court of Delhi, New Delhi
2.	Nature and details of the action(s) taken, initiated or order(s) passed	Restraining the Company from manufacturing, stockpiling, exporting, offering for sale and/or supplying, directly or indirectly, the pharmaceutical drug product containing the compound Ruxolitinib and/or Ruxolitinib Phosphate API along with any other form or compound or formulation which would amount to infringement of the Suit Patent bearing No. IN269841
3.	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	07 th October 2025
4.	Details of the violation(s)/ contravention(s) committed or alleged to be committed	Alleged violation of Patent Infringement IN269841 Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines and Pyrrolo [2,3-B] Pyrimidines as Janus Kinase Inhibitors
5.	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	No Financial impact

AARTI PHARMALABS LIMITED

www.aartipharmlabs.com | CIN : L24100GJ2019PLC110964 | Email : info@aartipharmlabs.com

Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234

Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655